00:09 , May 8, 2019 |  BC Extra  |  Company News

Regeneron falls after reporting EPS below the Street and disclosing patient deaths

Regeneron lost $2.4 billion in market cap Tuesday after reporting 1Q19 EPS well below consensus and disclosing two patient deaths in a Phase I trial evaluating its bispecific mAb targeting CD20 and CD3, REGN1979, in...
19:26 , Apr 30, 2019 |  BC Extra  |  Clinical News

April 30 Clinical Quick Takes: Xencor, Axovant, Cell Medica

Partial hold lifted on Xencor's blood cancer bispecific  FDA lifted a partial clinical hold on a Phase I trial of XmAb14045 from Xencor Inc. (NASDAQ:XNCR), which is evaluating the bispecific antibody against CD3 and CD123...
01:49 , Mar 22, 2019 |  BC Innovations  |  Targets & Mechanisms

Deconvoluting translation at Scripps

With three institutes now under one roof, Scripps Research has established both its own pipeline and a non-profit funding model to bring candidates through early stage clinical trials. Diverging from the philanthropy and investor-based approaches...
19:31 , Mar 1, 2019 |  BC Week In Review  |  Company News

WuXi, ABL expand deal to develop bispecifics

WuXi Biologics Inc. (HKSE:2269) granted ABL Bio Inc. (KOSDAQ:298380) rights to use WuXi's WuXiBody and CD3 platforms to develop and commercialize bispecific antibodies targeting an undisclosed immune checkpoint receptor. The partners said the deal expands...
04:45 , Feb 22, 2019 |  BC Innovations  |  Targets & Mechanisms

Solid checkpoint for CARs

PD-L1 family member B7-H3 could put CAR T cells in play for a slew of difficult-to-treat solid tumors, including pediatric cancers that lack targeted therapies, according to a pair of preclinical studies published this year....
23:49 , Feb 21, 2019 |  BC Week In Review  |  Clinical News

Partial hold for Phase I of Xencor's blood cancer bispecific

Xencor Inc. (NASDAQ:XNCR) said FDA placed a partial clinical hold on a Phase I trial of XmAb14045 following two patient deaths that were considered possibly related to treatment with the bispecific antibody against CD3 and...
20:01 , Feb 20, 2019 |  BC Extra  |  Clinical News

Partial hold for Phase I of Xencor's blood cancer bispecific

Xencor Inc. (NASDAQ:XNCR) said FDA placed a partial clinical hold on a Phase I trial of XmAb14045 following two patient deaths that were considered possibly related to treatment with the bispecific antibody against CD3 and...
01:35 , Feb 15, 2019 |  BC Week In Review  |  Company News

India's Glenmark spinning out innovative assets into U.S. unit

Glenmark Pharmaceuticals Ltd. (NSE:GLENMARK; BSE:532296) will spin out its innovation business to help accelerate its pipeline towards commercialization. The spinout will be a wholly owned subsidiary based in the U.S and have a new CEO...
21:47 , Feb 14, 2019 |  BC Extra  |  Company News

India's Glenmark spinning out innovative assets into U.S. unit

Glenmark Pharmaceuticals Ltd. (NSE:GLENMARK; BSE:532296) will spin out its innovation business to help accelerate its pipeline towards commercialization. The spinout will be a wholly owned subsidiary based in the U.S and have a new CEO...
23:21 , Feb 13, 2019 |  BC Week In Review  |  Company News

AbbVie gains option to Teneobio BCMA program

AbbVie Inc. (NYSE:ABBV) will pay $90 million up front for an option to acquire bispecific antibody TNB-383B from Teneobio Inc. (Menlo Park, Calif.), which would give AbbVie its first BCMA-targeted asset. TNB-383B targets BCMA and...